Undertaking 1 National 863 Project, 2 National Natural Science Foundations, 2 Major Key Research Projects of Shanghai Defense Science and Technology Commission, and 2 National Key Research Projects in the Eleventh Five-Year Plan; Mainly engaged in early diagnosis, comprehensive treatment, targeted treatment and individualized treatment of lung cancer, molecular imaging of tumors and phage vaccine. Awards and honors: 1994 and 2002 won the second prize of Anhui Science and Technology Progress respectively, ranking fourth and fifth respectively. In 2007, he was selected as the second batch of outstanding academic leaders of Shanghai Science and Technology Commission. Social part-time: member of the education Committee of IASLC (International Association for Lung Cancer Research); Standing Committee of Lung Cancer Committee of China Anti-cancer Association; Member of the Executive Committee of Clinical Cancer Collaboration Center of China Anti-Cancer Association; Standing Committee member of oncology Committee of China Geriatrics Association; Standing Committee of Cancer Branch of Chinese Medical Doctor Association; Member of Lung Cancer Group of Pulmonary Branch of Chinese Medical Association; Vice Chairman of Lung Cancer Professional Committee of Shanghai Anti-cancer Association; Member of Shanghai Pulmonary Science Society; Member of Shanghai Cancer Society; Member of respiratory professional Committee of Shanghai Association of Integrated Traditional Chinese and Western Medicine; Director of Shanghai Anti-cancer Association; Member of Shanghai Tumor Targeting Molecular Society.

Now he is the deputy editor of Lung Cancer (SCI impact factor 3.4); Editor-in-chief of Research on Transformed Lung Cancer; Standing Editorial Board of Chest Cancer; Editorial Committee of Journal of Thoracic Diseases; Oncology Editorial Board; Editorial Committee of China Oncology; Cancer Editorial Board; Editorial Committee of Sino-German Journal of Clinical Oncology; Editorial Committee of Journal of Tongji University; Editorial Committee of Clinical Oncology; Editorial Committee for Cancer Prevention and Treatment Research; Editorial Committee of International Journal of Respiratory Medicine; Editorial Board of China Journal of Cancer Prevention and Treatment

In 2008, OPTIMAL study (CTONG 0802), led by China, was the first international study on the first-line treatment of EGFR mutation lung cancer patients with single drug combined with chemotherapy. Its main clinical data were accepted by The Lancet Oncology, an international authoritative cancer journal, and published online on July 22nd, 201,and will be published in August. The Lancet Oncology is one of the three sub-journals of The The Lancet, and is regarded as the originator of modern medical journals. The annual impact factor of 20 1 1 is as high as 22.589. This is the first time that this magazine has published the clinical research results of experts in the field of lung cancer in China, and it is also the most influential clinical research paper on lung cancer published by experts in Chinese mainland so far.

Editor-in-Chief: New Comprehensive Therapy for Lung Cancer, Fudan University Press, September 2009.

Oncology Tongji University Press 20 10 1

Biological targeted therapy for lung cancer People's Health Publishing House 20 10 10

Expert diagnosis and treatment of lung diseases Shanghai Science and Technology Literature Publishing House 20 12 June